TORONTO, ONTARIO--(Marketwired - Feb. 16, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX
VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious
and unmet medical needs, today announced the Company is expanding its product pipeline through the development of
cannabinoid-based therapeutics targeting liver diseases.
"Through our dedicated bioinformatics platform specifically designed to identify repurposed and innovative drug and
plant-based treatments, such as cannabinoids, and with consultation of our experts in cannabinoid research, we have identified
potential cannabinoid-based lead opportunities in a number of liver diseases," said Craig Leon, Chief Executive Officer of
Revive. "We expect these initiatives to progress in the near-term and we will update the medical and investment communities
as they occur."
"This is a very exciting time for Revive as I have been working with them on a number of unique cannabinoid-based therapeutic
opportunities targeting liver diseases that we will be investigating in several pre-clinical research models," said Dr. Pritesh
Kumar, Scientific Advisor for the Company and Chief Executive Officer of PhytoSciences. "This is an area where we have
significant academic and clinical expertise and have coordinated the successful development of these research programs. I
look forward to establishing and advancing Revive's research initiatives in cannabinoid-based therapeutics that address both
well-known and rare liver diseases."
About Liver Disease
Liver disease is described by irregular functioning of liver, causing disorders like hepatitis, fatty liver, and
cirrhosis. There are over 100 described diseases of the liver affecting at least 30 million people alone in the U.S. A
number of factors are driving the liver disease treatment market, which include rapidly changing lifestyle patterns such as
increasing alcohol consumption, unhealthy diets, and increasing prevalence of liver diseases. Liver diseases can result from
injury to the liver caused by hepatitis C virus (HCV), hepatitis B virus (HBV), obesity, chronic excessive alcohol use or
autoimmune diseases. Major drug categories used in the treatment of liver diseases includes anti-rejection drugs, vaccines,
immunosuppressant, chemotherapy drugs and antiviral drugs. According to Allied Market Research, titled, "World Liver Disease
Treatment Market - Opportunities and Forecast, 2014 - 2022", the global market for liver disease treatment is projected to reach
$19,536 million by 2022.
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is focused on the research, development and commercialization of
novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and plant-based therapies,
such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs,
or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release includes certain information and statements about management's view of future events, expectations,
plans and prospects that constitute "forward-looking statements", which are not comprised of historical facts. Forward-looking
statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could",
"would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include,
without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential
efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion
of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the
Company's research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of
operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other
factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those
anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions
affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing
results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite
regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that
Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on
favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove
to be incorrect.
Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements
include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to
establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional
capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology
companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in
Revive's Management's Discussion & Analysis for the period ended June 30, 2016 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes
no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or
otherwise.
Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts
responsibility for the adequacy or accuracy of this release.